Praxis Patient Recruitment Campaign Saves 15 Months in Trial
Brentwood, Tenn.-February 5, 2009-Praxis, a company specializing in centralized patient recruitment for clinical research studies, recently provided patient recruitment services to a global pharmaceutical company for a study to test an investigational medication for a mental health indication. The recruitment program saved a combined 15 months for the 2-protocol program and delivered an 891% return on investment for one protocol and 539% return on investment for the second protocol.
Through Praxis’ upfront protocol feasibility analysis and target audience research, a customized & integrated marketing campaign was developed to increase awareness of the study in the communities surrounding the 90 participating clinical research sites. With only 75% of potential sites activating, 97% of total screenings and randomizations came from the Praxis supported sites utilizing the strategic marketing campaign which consisted of direct to patient branded advertising, on-site recruitment materials and electronic/online strategies.
Additionally, a comprehensive retention campaign was launched to encourage study compliance and completion by each subject. This resulted in a 91% retention rate-which is 30% greater than the industry average for phase III studies.
Praxis Communications, Inc., headquartered in Brentwood, Tenn., provides the pharmaceutical and biotech industries with a wide range of global services for patient recruitment and retention for clinical trials including patient profiling, recruitment planning, centralized fulfillment, media relations, advertising, and program management. For more information, call Praxis at (615) 312-8207 or visit
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025